Myasthenia Gravis (Chronic Weakness) Clinical Trials

A listing of Myasthenia Gravis (Chronic Weakness) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Safety Tolerability and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

immunosuppressive agents
generalized myasthenia gravis
ra101495
acetylcholine
corticosteroids
  • 97 views
  • 01 Aug, 2021
  • 160 locations
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, …

generalized myasthenia gravis
  • 0 views
  • 30 Jul, 2021
  • 38 locations
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).

immune globulin
igiv
generalized myasthenia gravis
rozanolixizumab
acetylcholine
  • 76 views
  • 01 Aug, 2021
  • 131 locations
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.

acetylcholine
serologic test
edrophonium chloride
acetylcholinesterase inhibitors
immunoglobulins
  • 18 views
  • 18 Jul, 2021
  • 15 locations